20.1 C
New York
Thursday, June 4, 2026

Tag: diet

newssourceFORcompanyinformationcontent1marketreleases

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with...

Châtillon, France, June 2, 2026

Ping An Launches “Ping An Home” Service Brand

Advancing Proactive Health Management to Meet Chinese Families' Demand for Healthy LongevityHONG KONG and SHANGHAI, June 2, 2026 /PRNewswire/ -- As population aging accelerates...

Ping An Launches “Ping An Home” Service Brand

Advancing Proactive Health Management to Meet Chinese Families' Demand for Healthy LongevityHONG KONG and SHANGHAI, June 2, 2026 /PRNewswire/ -- As population aging accelerates...

Nerve Soothe Launches All-New Nerve Support Formula in 2025 Amid Surging Interest in Natural Relief Solutions

Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support. 
Public curiosity around nerve health is rising in 2025, with searches, podcasts, and social platforms highlighting natural approaches. Nerve Soothe enters this conversation with a formula designed around ingredient transparency, plant-based extracts, and consumer-driven expectations for wellness support.

PurelyWHITE Deluxe Teeth Whitening Powder 2025 Report: Whiten Your Smile Instantly With Zero Sensitivity

An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care 
An In-Depth 2025 Analysis of PurelyWHITE Deluxe Teeth Whitening Powder and Consumer Trends in Sensitivity-Free Oral Care

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Breakthrough T1D-Authored Paper Paves the Way for Beta Cell Replacement Therapies on the Path to Cures for Type 1 Diabetes

Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits NEW YORK, Aug....

Functional Foods Market Surges to USD 654.45 Billion by 2033, Propelled by 10.4% CAGR – Verified Market Reports®

The Functional Foods Market is experiencing robust expansion, driven by rising consumer focus on health, wellness, and preventive nutrition. Growing demand for nutrient-enriched products,...

Functional Foods Market Surges to USD 654.45 Billion by 2033, Propelled by 10.4% CAGR – Verified Market Reports®

The Functional Foods Market is experiencing robust expansion, driven by rising consumer focus on health, wellness, and preventive nutrition. Growing demand for nutrient-enriched products,...

Vertigenics – The Natural Vertigo Breakthrough Driving 2025 Interest in Balance and Brain Support Formulas

Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025 
Public Interest in Natural Vertigo Support and Ingredient-First Balance Formulas Continues to Rise in 2025

AlphaCur Gains Momentum in 2025 as a Leading Formula for Neuropathy Nerve Health Support

AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025 
AlphaCur Introduces Ingredient-First Nerve Health Formula as Interest in Neuropathy Support and Long-Term Wellness Grows in 2025

OIKOS® Launches First-of-Its-Kind Cultured Dairy Drink Featuring A Patented Blend of Nutrients Designed to Help Build & Retain Muscle Mass During Weight Loss

New OIKOS FUSION™ is the first product in the yogurt category with a proprietary combination of whey, leucine and vitamin D designed to support...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

KeySlim Drops Explores Ingredient-First Weight Management Trends in 2025

A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals 
A Science-Backed Look at How KeySlim Drops’ Natural Formula Aligns With Evolving Healthy Weight Goals

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiet

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers